Compare TROW & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TROW | VTRS |
|---|---|---|
| Founded | 1937 | 1961 |
| Country | United States | United States |
| Employees | 4802 | 30000 |
| Industry | Investment Bankers/Brokers/Service | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.2B | 21.0B |
| IPO Year | 2000 | 2019 |
| Metric | TROW | VTRS |
|---|---|---|
| Price | $102.06 | $19.68 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 12 |
| Target Price | ★ $104.57 | $21.60 |
| AVG Volume (30 Days) | 1.9M | ★ 7.9M |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | ★ 4.96% | 2.41% |
| EPS Growth | ★ 0.98 | N/A |
| EPS | ★ 7.89 | N/A |
| Revenue | $2,370,700,000.00 | ★ $14,299,900,000.00 |
| Revenue This Year | $5.99 | $3.60 |
| Revenue Next Year | $1.02 | $3.46 |
| P/E Ratio | $13.30 | ★ N/A |
| Revenue Growth | ★ 26.65 | N/A |
| 52 Week Low | $85.22 | $10.39 |
| 52 Week High | $122.00 | $21.20 |
| Indicator | TROW | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 39.04 | 51.81 |
| Support Level | $100.47 | $16.02 |
| Resistance Level | $106.66 | $21.20 |
| Average True Range (ATR) | 3.37 | 0.59 |
| MACD | -0.64 | -0.10 |
| Stochastic Oscillator | 1.86 | 37.21 |
T. Rowe Price provides asset management services for individual and institutional investors. It offers a broad range of no-load US and international stock, hybrid, bond, and money market funds. At the end of August 2026, the firm had $1.897 trillion in managed assets, composed of equity (48%), balanced (37%), fixed-income and money market (12%), and alternative (3%) offerings. Close to two-thirds of managed assets are held in retirement-based accounts, which provide T. Rowe Price with a stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a US-based asset manager, deriving less than 10% of its AUM from overseas.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up one-third of Viatris' total sales. The remaining sales are derived from its portfolio of legacy products, including Lipitor, Norvasc, Lyrica, and Viagra.